Preclinical News and Research

RSS

TSRI researchers find way to change leukemia cells into leukemia-killing immune cells

Scientists at The Scripps Research Institute have found a way to change leukemia cells into leukemia-killing immune cells. The surprise finding could lead to a powerful new therapy for leukemia and possibly other cancers.

20 Oct 2015

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that yesterday it presented positive preclinical data demonstrating the promising potential of its lead product candidate VAL-083 (dianhydrogalactitol) as a treatment for ovarian cancer.

19 Oct 2015

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.

19 Oct 2015

US and German researchers team up to advance quality control of human stem cells

Researchers at The Scripps Research Institute (TSRI) in California, USA, and two German institutes, the Center for Integrated Psychiatry Kiel (ZIP) and the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, have announced a partnership to advance the quality control of human stem cells.

16 Oct 2015

Poorly-designed animal study threatens validity of preclinical research

Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to new a study from McGill University in Canada.

15 Oct 2015

Bio-molecules present in human breast milk can help resolve inflammation, combat infection

Human breast milk, which provides essential nutrients and antibodies to newborns, has long been known to play an important role in infant development and the immune system. In a new study published in Mucosal Immunology, researchers from Brigham and Women's Hospital report that human breast milk serves as a reservoir for bio-molecules that help to resolve inflammation and combat infection.

15 Oct 2015

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

An international research team led by scientists at the University of New Mexico Cancer Center discovered and developed a novel ligand peptide-mimic that inhibits abnormal overgrowth of blood vessels in retinal diseases and tumors. The discovery could lead to new drugs that keep cancers from growing. The team published a paper in the journal Science Translational Medicine.

15 Oct 2015

enGene, Janssen Biotech sign agreement to develop and commercialize new IBD therapies

enGene, Inc. a gene therapy company focused on development of therapeutics using its proprietary "Gene Pill" and enema gene delivery platform, today announced that it has entered into a definitive agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize new therapies for inflammatory bowel disease (IBD).

14 Oct 2015

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

A University of Colorado Cancer Center study recently published online ahead of print in the journal Oncotarget reports "robust antitumor activity" of the drug TAK-733 in cells and mouse models of colorectal cancer.

14 Oct 2015

MR Solutions launches MRS-PET system that allows simultaneous acquisition of PET and MRI imaging data

PET and MRI preclinical imaging systems can now be operated simultaneously for the first time by researchers. This follows the introduction of MR Solutions’ commercially available MRS-PET system which is inserted within the cryogen free 3T, 4.7T, or 7T MRI magnet.

From MR Solutions 14 Oct 2015

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Preclinical experiments led by a team of researchers at VCU Massey Cancer Center have shown that blocking the production of a protein known as chromodomain helicase DNA-binding protein 4 (CHD4) may help increase the effectiveness of first-line treatments for acute myeloid leukemia (AML), a particularly lethal blood cancer that is increasing in incidence among older adults.

14 Oct 2015

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

Eli Lilly and Company and ImaginAb Inc. are pleased to announce a preclinical research collaboration to study potential novel T-cell-based immuno-oncology therapies.

13 Oct 2015

ATA announces first-year research grants to support promising young researchers

The American Thyroid Association (ATA) is pleased to announce the awarding of first-year grants to support two young researchers selected from among a pool of applicants who proposed projects that will contribute novel insights and information with the potential to lead to new drug targets and therapeutic strategies to improve the treatment of thyroid cancer and patient outcomes.

13 Oct 2015

Antiviral agent protects rhesus monkeys from deadly Ebola virus

Rhesus monkeys were completely protected from the deadly Ebola virus when treated three days after infection with a compound that blocks the virus's ability to replicate. These encouraging preclinical results suggest the compound, known as GS-5734, should be further developed as a potential treatment, according to research findings to be presented tomorrow at the IDWeek conference.

12 Oct 2015

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Disabling a cancer-causing pathway and administering an immune-molecule-based mop-up therapy eradicated a specific type of breast tumor in mice, according to researchers in the Perelman School of Medicine at the University of Pennsylvania.

8 Oct 2015

Wake Forest Baptist Medical Center announces creation of Technology Development Program

Wake Forest Baptist Medical Center today announced the creation of a Technology Development Program, a $15 million program to develop the ideas, discoveries and inventions of the faculty and staff of the Medical Center into life science technologies having the potential to benefit patients in the community and worldwide.

8 Oct 2015

Dr. Paul Liu named 2015 Distinguished Alumnus for contributions to leukemia research

In his laboratory in the National Human Genome Research Institute in Bethesda, Md., Paul Liu, M.D., Ph.D., is working on targeted treatments for leukemia, a life-threatening blood cancer.

8 Oct 2015

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients.

6 Oct 2015

Vertera Spine receives FDA 510(k) clearance for COHERE Cervical Interbody Fusion Device

Vertera Spine, a developer of medical devices with advanced functional surface technologies for spine applications, today announced it has received U.S. Food and Drug Administration 510(k) clearance for its COHERE Cervical Interbody Fusion Device.

6 Oct 2015

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).

6 Oct 2015

Preclinical News and Research

TSRI researchers find way to change leukemia cells into leukemia-killing immune cells

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

US and German researchers team up to advance quality control of human stem cells

Poorly-designed animal study threatens validity of preclinical research

Bio-molecules present in human breast milk can help resolve inflammation, combat infection

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

enGene, Janssen Biotech sign agreement to develop and commercialize new IBD therapies

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

MR Solutions launches MRS-PET system that allows simultaneous acquisition of PET and MRI imaging data

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Lilly, ImaginAb partner to study potential novel T-cell-based immuno-oncology therapies

ATA announces first-year research grants to support promising young researchers

Antiviral agent protects rhesus monkeys from deadly Ebola virus

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Wake Forest Baptist Medical Center announces creation of Technology Development Program

Dr. Paul Liu named 2015 Distinguished Alumnus for contributions to leukemia research

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Vertera Spine receives FDA 510(k) clearance for COHERE Cervical Interbody Fusion Device

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics